Successful desensitization to brentuximab vedotin after anaphylaxis

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 2, 2014, Pages

  O'connell, Amy E ^a   Lee, Joyce P ^a   Yee, Christina ^a   Kesselheim, Jennifer ^b   Dioun, Anahita ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Anaphylaxis; Anaplastic large cell lymphoma; Brentuximab vedotin; Desensitization; Drug allergy

Indexed keywords

ADRENALIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CETIRIZINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; FAMOTIDINE; GABAPENTIN; HYDROCORTISONE; IFOSFAMIDE; METHOTREXATE; NARCOTIC AGENT; PARACETAMOL; RANITIDINE; SALBUTAMOL; SODIUM CHLORIDE; STEROID; VEDOTIN; VINBLASTINE; VINCRISTINE; ANTIBODY CONJUGATE; CAC10-VCMMAE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANALGESIA; ANAPHYLAXIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; DESENSITIZATION; DRUG HYPERSENSITIVITY; GRAFT VERSUS HOST REACTION; HUMAN; INDUCTION CHEMOTHERAPY; INFUSION RATE; INGUINAL LYMPH NODE; INTRAVENOUS ADMINISTRATION; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHIC PAIN; PATIENT MONITORING; PERSONALIZED MEDICINE; PRURITUS; SKIN NECROSIS; SKIN TEST; STEROID THERAPY; TREATMENT OUTCOME; YOUNG ADULT; LYMPHOMA, LARGE-CELL, ANAPLASTIC; PROCEDURES;

ANAPHYLAXIS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896376487     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.11.003     Document Type: Article

References (11)

1. J. Vadakara, and B. Pro Targeting CD30 in anaplastic large cell lymphoma Curr Hematol Malign Rep 7 2012 285 291.
2. J.A. Francisco, C.G. Cerveny, and D.L. Meyer et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 102 2003 1458 1465.
3. A. Younes, N.L. Bartlett, and J.P. Leonard et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N Engl J Med 363 2010 1812 1821.
4. B. Pro, R. Advani, and P. Brice et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study J Clin Oncol 30 2012 2190 2196.
5. P.J. Brennan, T. Rodriguez Bouza, F.I. Hsu, D.E. Sloane, and M.C. Castells Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment J Allergy Clin Immunol 124 2009 1259 1266.
6. G. Seifert, T. Reindl, S. Lobitz, K. Seeger, and G. Henze Fatal course after administration of rituximab in a boy with relapsed ALL: a case report and review of literature Haematologica 91 2006 ECR23.
7. P.J. Bugelski, R. Achuthanandam, R.J. Capocasale, G. Treacy, and E. Bouman-Thio Monoclonal antibody-induced cytokine-release syndrome Exp Rev Clin Immunol 5 2009 499 521.
8. H.S. Kulkarni, and P.M. Kasi Rituximab and cytokine release syndrome Case Rep Oncol 5 2012 134 141.
9. P.M. Kasi, H.A. Tawbi, C.V. Oddis, and H.S. Kulkarni Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective Crit Care 16 2012 231.
10. D.I. Hong, L. Bankova, K.N. Cahill, T. Kyin, and M.C. Castells Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies Exp Rev Clin Immunol 8 2012 43 52 quiz 53-54.
11. A. Vultaggio, A. Matucci, and F. Nencini et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab Int Arch Allerg Immunol 159 2012 321 326